320 related articles for article (PubMed ID: 31021531)
1. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
Hofmarcher T; Borg S
J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
[TBL] [Abstract][Full Text] [Related]
3. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact.
Rognoni C; Gerzeli S
J Comp Eff Res; 2019 Oct; 8(13):1099-1110. PubMed ID: 31580153
[No Abstract] [Full Text] [Related]
4. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
[TBL] [Abstract][Full Text] [Related]
5. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P
Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
Hofmarcher T; Cabrales Alin D; Linde C
Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
[TBL] [Abstract][Full Text] [Related]
7. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
Brock E; Braunhofer P; Troxler J; Schneider H
Eur J Health Econ; 2014 Dec; 15(9):907-16. PubMed ID: 24081613
[TBL] [Abstract][Full Text] [Related]
9. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
Gutzwiller FS; Schwenkglenks M; Blank PR; Braunhofer PG; Mori C; Szucs TD; Ponikowski P; Anker SD
Eur J Heart Fail; 2012 Jul; 14(7):782-90. PubMed ID: 22689292
[TBL] [Abstract][Full Text] [Related]
10. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose: a review of its use in iron deficiency.
Keating GM
Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
[TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
13. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Bager P; Dahlerup JF
J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
[TBL] [Abstract][Full Text] [Related]
14. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
15. [Economic impact of ferric carboxymaltose in haemodialysis patients].
Aiello A; Berto P; Conti P; Panichi V; Rosati A
G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
[TBL] [Abstract][Full Text] [Related]
16. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.
Delgado JF; Oliva J; González-Franco Á; Cepeda JM; García-García JÁ; González-Domínguez A; Garcia-Casanovas A; Jiménez Merino S; Comín-Colet J
J Med Econ; 2020 Dec; 23(12):1418-1424. PubMed ID: 33073660
[TBL] [Abstract][Full Text] [Related]
17. Ferric Carboxymaltose: A Review in Iron Deficiency.
Scott LJ
Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W
ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751
[TBL] [Abstract][Full Text] [Related]
20. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany.
Theidel U; Väätäinen S; Martikainen J; Soini E; Hardt T; Doehner W
ESC Heart Fail; 2017 Aug; 4(3):274-281. PubMed ID: 28772041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
